Mecasermin
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Pregnancy category |
|
| Legal status |
|
| Routes of administration | Subcutaneous |
| Identifiers | |
| CAS Number |
68562-41-4  |
| ATC code | H01AC03 |
| DrugBank |
DB01277 |
| ChemSpider | none |
| UNII |
7GR9I2683O  |
| KEGG |
D04870 |
| ChEMBL |
CHEMBL1201716 |
| Chemical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.67 g/mol |
| (what is this?) (verify) | |
Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]
This drug is not to be confused with mecasermin rinfabate (trade name Iplex), which is a combination of recombinant human IGF-1 (rhIGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.
References
- ↑ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
- ↑ "Increlex". Drugs.com. Retrieved 10 January 2010.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.